Navigation Links
Phase 3 Open-Label Study Comparing Tapentadol Extended Release Tablets to Oxycodone Controlled Release Tablets Published by Pain Practice
Date:7/19/2010

ratory depression with carbon dioxide retention. Therefore, NUCYNTA® should not be used in patients susceptible to the effects of raised cerebrospinal fluid pressure such as those with head injury and increased intracranial pressure. Opioid analgesics may obscure the clinical course of patients with head injury due to effects on pupillary response and consciousness. NUCYNTA® should be used with caution in patients with head injury, intracranial lesions, or other sources of preexisting increased intracranial pressure.

NUCYNTA® is a mu-opioid agonist and is a Schedule II controlled substance. Such drugs are sought by drug abusers and people with addiction disorders. Diversion of Schedule II products is an act subject to criminal penalty. NUCYNTA® can be abused in a manner similar to other mu-opioid agonists, legal or illicit. This should be considered when prescribing or dispensing NUCYNTA® in situations where the physician or pharmacist is concerned about an increased risk of misuse and abuse. All patients treated with mu-opioid agonists require careful monitoring for signs of abuse and addiction. NUCYNTA® may be abused by crushing, chewing, snorting or injecting the product. These practices pose a significant risk to the abuser that could result in overdose and death.

Experience with NUCYNTA® overdose is very limited. Management of overdose should be focused on treating symptoms of mu-opioid agonism. Primary attention should be given to reestablishment of a patent airway and institution of assisted or controlled ventilation when overdose of NUCYNTA® is suspected. Supportive measures (including oxygen and vasopressors) should be employed in the management of circulatory shock and pulmonary edema accompanying overdose as indicated. Cardiac arrest or arrhythmias may require cardiac massage or defibrillation.

Patients should be cautione
'/>"/>

SOURCE PriCara
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015 Biosensors ... BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, ... announced financial results for its first fiscal quarter ... Quarter Highlights and Recent Developments: ... in improving its cost structure, driven by lower ...
(Date:8/3/2015)... 3, 2015  Array BioPharma Inc. (NASDAQ: ... quarter and full year of its fiscal year ... Chief Executive Officer of Array, noted, "Binimetinib and encorafenib, ... on track for regulatory submissions in 2016. Additional ... and BRAF-mutant colorectal cancer further validate the value ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
Breaking Medicine Technology:Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... 2011 Graymark Healthcare Inc. (Nasdaq: ... diagnostic sleep services and an innovator in comprehensive care for ... patients in the fourth quarter of 2010, with a 16% ... shipments, as compared to fourth quarter of 2009. ...
... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) ... Isis, Development PipelineWhen: , Thursday, January 06, 2011 ... , www.isispharm.comHow: , Live on the Internet.  Simply ... , Kristina LemonidisDirector, Investor Relations(760) 603-2490Amy Blackley, Ph.D.Assistant ...
Cached Medicine Technology:Graymark Healthcare's Sleep Apnea Therapy Program Services Record Number of Patients in Q4 2010 2Graymark Healthcare's Sleep Apnea Therapy Program Services Record Number of Patients in Q4 2010 3
(Date:8/3/2015)... ... , ... The art of preparing and cooking food comes naturally to some. ... age, Nasreen Zereshki was extremely eager to cook Persian cuisine. Now that she is ... Persian Kitchen with the world. , Since Americans tend to be undereducated about Persian ...
(Date:8/3/2015)... Alachua, FL (PRWEB) , ... August 03, 2015 , ... ... peripheral nerve injuries, is scheduled to present at the Wedbush Healthcare Conference on Wednesday, ... , A live webcast and subsequent archived replay of the Company’s presentation may be ...
(Date:8/3/2015)... ... 03, 2015 , ... It’s 25 miles from remote Medicine ... and among its least visited State Parks. The volcanic area beneath Medicine Lake ... at Ahjumawi Lava Springs, part of the Fall River Springs complex. * According ...
(Date:8/3/2015)... ... 03, 2015 , ... A July 9 article from USA Today ... according to the American Dental Association. According to a study by the American Dental ... million in a single year to 2.2 million a year. Dentists and ADA officials ...
(Date:8/3/2015)... ... 03, 2015 , ... From 2006-2017 the number of dental ... market research compiled for the National Association of Dental Laboratories ( NADL ) ... of Labor Statistics. As the number of dental laboratories decreases, dentists will have ...
Breaking Medicine News(10 mins):Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3
... 21 In this unstable economic,environment characterized by ... competition in the,bio/pharma marketplace, retaining your most-valued customers ... posts - from web interactions,and early warning systems ... toward,defining the superior customer experience. , ...
... invited to participate with U.S. Secretary of Health, Michael Leavitt, in ... ... Salt Lake City (Vocus) November 20, 2008 -- MediConnect CEO, ... Health, Michael Leavitt, in the 2008 National Summit on Personalized Health ...
... and Extremely Intuitive to Navigate, Making Shopping for Safety Products Easier ... ... 2008 -- Conney Safety Products is proud to announce that their ... state-of-the-art technology. The new website is faster, more efficient and features ...
... D. and Catherine T. MacArthur Foundation is creating a new ... and opportunities posed by our aging society. In the ... an aging society, one feature of which is that those ... Although the nation will become increasingly gray in subsequent decades, ...
... returned positive results in review of national program , , ... detects 40 percent of cancers and should be carefully ... researchers. , They studied 106,000 people, aged 60 to ... program was in identifying unrecognized disease. Half the people ...
... (NMQF) today applauded the American Medical Association,s recent decision to ... physician and patient advocates to join the Forum in encouraging ... , "Physicians and lawyers -- even politicians -- ... Chief Executive Officer of the Forum. "It,s long past time ...
Cached Medicine News:Health News:Creating Brand Advocates by Delivering the Superior Total Customer Experience 2Health News:MediConnect Participates in 2008 National Health Summit 2Health News:Conney Safety Products, Leader in Safety Equipment and Supplies, Launches New Website 2Health News:New MacArthur network to examine impact of aging society 2Health News:Colorectal Cancer Screens Detect Unrecognized Disease 2Health News:National Minority Quality Forum Applauds AMA's Health Insurer Code of Conduct 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: